228 related articles for article (PubMed ID: 3392995)
1. Anticoagulant effects of protamine sulfate in a canine model.
Kresowik TF; Wakefield TW; Fessler RD; Stanley JC
J Surg Res; 1988 Jul; 45(1):8-14. PubMed ID: 3392995
[TBL] [Abstract][Full Text] [Related]
2. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
3. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.
Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Stoneham MD; Doyle AR; Zelenock GB; Jacobs LA; Shanley CJ; TenCate VM; Stanley JC
J Vasc Surg; 1997 Dec; 26(6):1043-8. PubMed ID: 9423721
[TBL] [Abstract][Full Text] [Related]
4. The effect of protamine sulfate on platelet function.
Lindblad B; Wakefield TW; Whitehouse WM; Stanley JC
Scand J Thorac Cardiovasc Surg; 1988; 22(1):55-9. PubMed ID: 3387950
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model.
Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Downing LJ; Stanley JC
Lab Anim Sci; 1997 Apr; 47(2):153-60. PubMed ID: 9150494
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal.
DeLucia A; Wakefield TW; Andrews PC; Nichol BJ; Kadell AM; Wrobleski SK; Downing LJ; Stanley JC
J Vasc Surg; 1993 Jul; 18(1):49-58; discussion 58-60. PubMed ID: 8326659
[TBL] [Abstract][Full Text] [Related]
7. Depressed cardiovascular function and altered platelet kinetics following protamine sulfate reversal of heparin activity.
Wakefield TW; Whitehouse WM; Stanley JC
J Vasc Surg; 1984 Mar; 1(2):346-55. PubMed ID: 6481883
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the quantitative action of protamine and heparin on blood coagulation. Significance in clinical and laboratory usage.
Perkash A
Am J Clin Pathol; 1980 May; 73(5):676-81. PubMed ID: 7377134
[TBL] [Abstract][Full Text] [Related]
9. Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.
Brecher AS; Hellman K; Basista MH
Dig Dis Sci; 1999 Jul; 44(7):1349-55. PubMed ID: 10489917
[TBL] [Abstract][Full Text] [Related]
10. Platelet damage by protamine and the protective effect of prostacyclin: an experimental study in dogs.
Velders AJ; Wildevuur CR
Ann Thorac Surg; 1986 Aug; 42(2):168-71. PubMed ID: 3527093
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of hemodynamic and hematologic effects of heparin-protamine sulfate interaction after aortic reconstruction in a canine model.
Wakefield TW; Lindblad B; Whitehouse WM; Hantler CB; Stanley JC
Surgery; 1986 Jul; 100(1):45-51. PubMed ID: 3726760
[TBL] [Abstract][Full Text] [Related]
12. Haemodynamic and haematologic alterations with protamine reversal of anticoagulation: comparison of standard heparin and a low molecular weight heparin fragment.
Lindblad B; Borgström A; Wakefield TW; Whitehouse WM; Stanley JC
Eur J Vasc Surg; 1987 Jun; 1(3):181-5. PubMed ID: 2846368
[TBL] [Abstract][Full Text] [Related]
13. Confounding effect of therapeutic protamine and heparin levels on routine and special coagulation testing.
Khandelwal A; Phua CW; Chaudhry HR; Tsui H; Rivard GE; Teitel JM; Sholzberg M
Blood Coagul Fibrinolysis; 2020 Jan; 31(1):60-64. PubMed ID: 31904611
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
[TBL] [Abstract][Full Text] [Related]
15. Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?
Gertler R; Wiesner G; Tassani-Prell P; Braun SL; Martin K
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):981-6. PubMed ID: 21315618
[TBL] [Abstract][Full Text] [Related]
16. Increased prostacyclin and adverse hemodynamic responses to protamine sulfate in an experimental canine model.
Wakefield TW; Wrobleski SK; Wirthlin DJ; Wang TW; Stanley JC
J Surg Res; 1991 May; 50(5):449-56. PubMed ID: 2038184
[TBL] [Abstract][Full Text] [Related]
17. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass.
Bernabei A; Gikakis N; Maione TE; Kowalska MA; Yan Z; Niewiarowski S; Edmunds LH
J Thorac Cardiovasc Surg; 1995 Apr; 109(4):765-71. PubMed ID: 7715225
[TBL] [Abstract][Full Text] [Related]
18. Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Fazzalari A; Nichol BJ; Vanderkooi T; Stanley JC
J Surg Res; 1994 Jun; 56(6):586-93. PubMed ID: 8015315
[TBL] [Abstract][Full Text] [Related]
19. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations.
Bolliger D; Szlam F; Azran M; Koyama K; Levy JH; Molinaro RJ; Tanaka KA
Anesth Analg; 2010 Sep; 111(3):601-8. PubMed ID: 20686004
[TBL] [Abstract][Full Text] [Related]
20. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation.
Ni Ainle F; Preston RJ; Jenkins PV; Nel HJ; Johnson JA; Smith OP; White B; Fallon PG; O'Donnell JS
Blood; 2009 Aug; 114(8):1658-65. PubMed ID: 19531655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
